SCHEMBL5773007

SCHEMBL5773007

CCC(CC)(c1ccc(NC(=O)CCc2cnoc2-c2cc(C)cs2)cc1)P(=O)(O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.34
LMNA P02545 4/20 0.34
TP53 P04637 3/20 0.34
CYP2C19 P33261 3/20 0.34
RAB9A P51151 3/20 0.34
HTT P42858 2/20 0.34
CYP3A4 P08684 2/20 0.34
NPC1 O15118 2/20 0.34
GMNN O75496 1/20 0.34
CYP1A2 P05177 1/20 0.34
HTR1A P08908 1/20 0.34
THRB P10828 1/20 0.34
PIM1 P11309 1/20 0.34
CYP2C9 P11712 1/20 0.34
MAOA P21397 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
AGTR1 P30556 1/20 0.34
CCKBR P32239 1/20 0.34
MC4R P32245 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5774793 0.84 KDM4E (0.37) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5771724 0.82 MAPT (0.41) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5771812 0.81 MAPT (0.38) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5775864 0.80 SMN1; SMN2 (0.47) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5777446 0.80 MEN1 (0.41) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5771355 0.80 MAPT (0.39) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5777020 0.80 MAPT (0.42) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5773239 0.80 MAPT (0.37) SMN1; SMN2LMNATP53CYP2C19RAB9A
SCHEMBL5771188 0.79 CNR2 (0.43) CNR2HDAC1
SCHEMBL5772996 0.79 MAPT (0.36) SMN1; SMN2LMNATP53CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR SMN1; SMN2 3383/4885LMNA 2770/4885TP53 4371/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 SMN1; SMN2 2449/4885LMNA 2605/4885TP53 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.